.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 8,932,635

« Back to Dashboard

Details for Patent: 8,932,635

Title:Pharmaceutical compositions of hydrophobic surface-modified active substance microparticles for inhalation
Abstract: The invention provides microparticles for use in a pharmaceutical composition for pulmonary administration, each microparticle comprising a particle of an active substance having, on its surface, particles of a hydrophobic material suitable for delaying the dissolution of the active substance. The invention also provides a method for making the microparticles.
Inventor(s): Staniforth; John Nicholas (Bath, GB), Harris; Haggis (Bristol, GB), Morton; David Alexander Vodden (Bath, GB), Bannister; Robin (Essex, GB)
Assignee: Vectura Limited (Wiltshire, GB)
Filing Date:Mar 27, 2013
Application Number:13/851,205
Claims:1. Microparticles for use in a pharmaceutical composition for pulmonary administration, comprising particles of an active substance having, on their surfaces, particles of a hydrophobic material comprising magnesium stearate suitable for promoting the dispersal of the active particles on actuation of an inhaler and suitable for delaying the dissolution of the active substance, the microparticles being such that the active substance exerts its pharmacological effect over a period of greater than 12 hours and the microparticles comprise a rapidly dissolving active substance under the conditions obtained in the lung, wherein the microparticles comprise an effective amount of at least one of the substances selected from the group consisting of an antimuscarinic substance, a .beta.2-agonist, a steroid, a peptide and a polypeptide.

2. Microparticles according to claim 1 in which the hydrophobic material comprises a phospholipid.

3. Microparticles according to claim 1 which comprise not more than 90% of the hydrophobic material based on the total weight of the microparticles.

4. Microparticles according to claim 1 having a mass median aerodynamic diameter of not more than 10 .mu.m.

5. Microparticles as claimed in claim 1 which are in the form of agglomerated microparticles.

6. Microparticles as claimed in claim 1 which have at least a partial coating of a film-forming material.

7. Microparticles as claimed in claim 1 being such that, upon inhalation of the microparticles, the active substance exerts its pharmacological effect over a period significantly greater than the period over which the active substance exerts its pharmacological effect when inhaled alone.

8. Microparticles as claimed in claim 1 comprising a rapidly dissolving active substance under the conditions obtained in the lung, the microparticles having a rate of dissolution no greater than 80% of the rate of dissolution of particles of the active substance.

9. Microparticles as claimed in claim 1 which do not comprise an effective amount of an antimuscarinic agent.

10. Microparticles as claimed in claim 1 in which the particles of hydrophobic material are present as a coating on the surfaces of the particles of active substance.

11. Microparticles as claimed in claim 10 in which the coating is a discontinuous coating.

12. Microparticles as claimed in claim 1 which are a powder for use in a dry powder inhaler.

13. A composition for inhalation comprising microparticles as claimed in claim 1.

14. A composition as claimed in claim 13 which is a dry powder and is suitable for use in a dry powder inhaler.

15. A composition as claimed in claim 14 which comprises carrier particles.

16. A composition as claimed in claim 13 which further comprises a propellant and is suitable for use in a pressurised metered dose inhaler.

17. A method of preparing microparticles for use in a pharmaceutical composition for pulmonary administration, comprising particles of active substance having, on their surfaces, particles of a hydrophobic material comprising magnesium stearate suitable for promoting the dispersal of the active particles on actuation of an inhaler and suitable for delaying the dissolution of the active substance, the method comprising the step of combining particles of the active substance with particles of the hydrophobic material, the microparticles being such that the active substance exerts its pharmacological effect over a period of greater than 12 hours and the microparticles comprise a rapidly dissolving active substance under the conditions obtained in the lung, wherein the microparticles comprise an effective amount of at least one of the substances selected from the group consisting of an antimuscarinic substance, a .beta.2-agonist, a steroid, a peptide and a polypeptide.

18. A method as claimed in claim 17 in which particles of the active substance are milled in the presence of the particles of the hydrophobic material.

19. A method according to claim 18 in which the milling step involves ball milling.

20. A method according to claim 18 in which the milling step involves passing a mixture of the particles of hydrophobic material and the particles of active material, in a liquid, through a constriction under pressure.

21. A method according to claim 19 in which the milling step involves compressing a mixture of the active particles and particles of hydrophobic material in a gap of predetermined width.

22. A method as claimed in claim 17 in which particles comprising the active substance are combined with the hydrophobic material in a spray drying step.

23. A method of pulmonary administration of the active substance comprising a step of administering a composition as claimed in claim 13 to a person in need thereof.

24. A method of using magnesium stearate in a pharmaceutical composition comprising preparing a milled active substance with magnesium stearate on the surface of the active substance formed into microparticles for pulmonary administration, to promote the dispersal of the milled active substance on actuation of an inhaler and to delay the dissolution of the active substance in the lung, and administering the substance with magnesium stearate on the surface of the active substance to a patient in need, and the milled active substance comprising a rapidly dissolving active substance under the conditions obtained in the lung, wherein the milled active substance comprises an effective amount of at least one or the substances selected from the group consisting of an antimuscarinic substance, a .beta.2-agonist, a steroid, a peptide and a polypeptide.

25. The method of claim 24 wherein the rate of dissolution of the active substance is reduced by at least 20%.

26. A method of preparing microparticles exhibiting delayed dissolution for use in a pharmaceutical composition for pulmonary administration, comprising the step of combining particles of an active substance with particles of a hydrophobic material in a spray drying step, wherein the hydrophobic material comprises magnesium stearate suitable for promoting the dispersal of the active particles on actuation of an inhaler and suitable for delaying the dissolution of the active substance and wherein the magnesium stearate is on the surface of the active substance formed in the microparticles, the microparticles being such that the active substance exerts its pharmacological effect over a period of greater than 12 hours and the microparticles comprise a rapidly dissolving active substance under the conditions obtained in the lung, wherein the microparticles comprise an effective amount of at least one of the substances selected from the group consisting of an antimuscarinic substance, a .beta.2-agonist, a steroid, a peptide and a polypeptide.

27. The method as claimed in claim 26, in which the spray-drying step involves spray-drying a suspension comprising the particles of active substance and the particles of hydrophobic material.

28. The method as claimed in claim 27, in which a film-forming material is dissolved in the suspension.

29. The method as claimed in claim 26, wherein the droplets formed during the spray-drying process are in the range of 1-20 .mu.m in diameter.

30. The method as claimed in claim 26, wherein the inlet temperature in the spray drying step is in the range of 50-150.degree. C.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc